openPR Logo
Press release

Cardiomyopathy Market Share 2023: Trends, Key Players, Industry Analysis and Forecast 2023-2029

04-12-2023 11:15 AM CET | Health & Medicine

Press release from: Orion Market Research

Cardiomyopathy Market Share 2023: Trends, Key Players,

The global cardiomyopathy market is anticipated to grow at a considerable CAGR of 4.2% during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace this is anticipated to hold significant growth. For instance, In April 2022, LianBio's and Bristol-Myers Squibb partnered and developed Camzyos medicine which has been approved by U.S. Food and Drug Administration (FDA). This is developed for the treatment class II-III obstructive hypertrophic cardiomyopathy for cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Similarly, in November 2021, Sanofi has partnered with MyoKardia, both in partnership will develop and discover targeted therapeutics to treat patients with genetic heart disease. The partnership is mainly for three programs, in that two are focused on hypertrophic cardiomyopathy (HCM), while the other one is on dilated cardiomyopathy (DCM).

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiomyopathy-market

Furthermore, in May 2020, BioMarin Pharmaceutical Inc. and DiNAQOR AG collaborated to develop gene therapy to treat rare genetic cardiomyopathies. The new partnership is under DiNAQOR's lead program in which DiNA-001 for MYBPC3 hypertrophic cardiomyopathy is being licensed. This is developing focused on the treatment of MYBPC3-linked cardiomyopathy. Whereas, in September 2019, Abbott has received FDA approval for its troponin blood test, which identifies heart attacks hours earlier than previous methods being used. Moreover, it has also launched a training partnership program to help the US hospital staff incorporate the automated blood test into their ER workflows and guide them about new tests developed.

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
o By Product

o By Technology

o By Application

Regions Covered-
o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Becton and Dickson & Co., Boston Scientific Corp., Mylan N.V, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Cardiomyopathy Market Report Segment

By Type

Dilated Cardiomyopathy
Restrictive Cardiomyopathy
Unclassified Cardiomyopathy
Hypertrophic Cardiomyopathy
Arrhythmogenic Right Ventricular Dysplasia's

By Diagnosis Test

Blood Tests
Cardiac MRI
Chest X-Ray
Cardiac CT Scan
Echocardiogram
Treadmill Stress Test
Electrocardiogram (Ecg)
Cardiac Catheterization
Genetic Testing or Screening

By Treatment

Medication
Nonsurgical Procedures
o Septal Ablation

o Radiofrequency Ablation

Surgery
o Septal Myectomy

o Heart Transplant

By End-User

Homecare
Hospitals And Clinics
Diagnostic Center
Other

A full report of Cardiomyopathy Market is available at: https://www.omrglobal.com/industry-reports/cardiomyopathy-market

Cardiomyopathy Market- Segment by Region

North America

United States
Canada

Europe

Germany
United Kingdom
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

Abbott
AstraZeneca
Becton, Dickinson and Co.
BIOMÉRIEUX, INC.
Bio-Rad Laboratories, Inc
Boston Scientific Corp.
Bristol-Myers Squibb Co.
Hoffmann-La Roche Ltd
Ionis Pharmaceuticals
Janssen Pharmaceuticals, Inc.
Laboratory Corp.
Medtronic Plc.
Merck & Co., Inc.
Mylan N.V.

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Visit more report at

https://www.culturespace.co.kr/news-%eb%ac%b8%ed%99%94%e8%a1%97/%ec%bc%80%ec%9d%b4%eb%b8%94-%eb%aa%a8%eb%8e%80-%ec%a2%85%eb%8b%a8-%ec%8b%9c%ec%8a%a4%ed%85%9c-%ec%8b%9c%ec%9e%a5-%ea%b7%9c%eb%aa%a8-%ec%a0%90%ec%9c%a0%ec%9c%a8-%ec%9d%b8%ec%83%81%ec%a0%81%ec%9d%b8/46783/

https://www.asiatimeskorea.com/press-release/%ea%b1%b4%ec%84%a4-%eb%a1%9c%eb%b4%87-%ec%8b%9c%ec%9e%a5-%ec%a0%90%ec%9c%a0%ec%9c%a8-2023-%eb%8f%99%ed%96%a5-%ec%a3%bc%ec%9a%94-%ec%97%85%ec%b2%b4-%ec%82%b0%ec%97%85-%eb%b6%84%ec%84%9d-%eb%b0%8f/411325/

https://monblogapple.com/2023/03/24/croissance-du-marche-du-stockage-en-reseau-grand-public-rapport-danalyse-tendances-et-apercu-2023-2029/

https://revistaeconomiasocial.com/2023/03/24/contact-center-analytics-tendencias-del-mercado-informe-de-investigacion-crecimiento-oportunidades-pronostico-2023-2029/

https://sportmsr.com/%d8%aa%d9%82%d8%b1%d9%8a%d8%b1-%d8%b3%d9%88%d9%82-%d8%aa%d8%b5%d9%86%d9%8a%d8%b9-%d8%b9%d9%82%d9%88%d8%af-%d8%a7%d9%84%d8%b3%d9%8a%d8%a7%d8%b1%d8%a7%d8%aa-2023-%d8%ad%d8%b3%d8%a8-%d8%a7%d9%84%d9%84-2/

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cardiomyopathy Market Share 2023: Trends, Key Players, Industry Analysis and Forecast 2023-2029 here

News-ID: 3009472 • Views:

More Releases from Orion Market Research

AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2033
AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2 …
AI-enabled imaging modalities market was valued at approximately USD 1.36 billion, and it is projected to reach around USD 19.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 34.67% from 2024 to 2033. AI-Enabled Imaging Modalities Market Overview The AI-enabled imaging modalities market is experiencing rapid growth, driven by advancements in artificial intelligence and machine learning technologies. These innovations are enhancing the capabilities of various imaging modalities, including
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Playe …
Global tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing incidence of cancer and advancements in imaging and tracking technologies. These systems improve the precision of
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry Growths to 2033
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry …
Tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing prevalence of cancer and advancements in imaging technologies. These systems play a crucial role in enhancing the
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and G …
SNP genotyping market was valued at approximately USD 31.66 billion, and it is projected to reach around USD 238.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 20.1% from 2024 to 2034. SNP genotyping Market Overview The SNP genotyping market is experiencing significant growth, driven by advancements in genotyping technologies, an increase in the prevalence of genetic disorders, and the expansion of pharmacogenomics and precision medicine initiatives. This

All 5 Releases


More Releases for Cardiomyopathy

Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Hypertrophic Cardiomyopathy Market - Empowering Lives, Elevating Heart Health: H …
Newark, New Castle, USA: The "Hypertrophic Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hypertrophic Cardiomyopathy Market: https://www.growthplusreports.com/report/hypertrophic-cardiomyopathy-market/8833 This latest report researches the industry structure, sales, revenue,
Dilated Cardiomyopathy Market - Rebuilding Hope, Restoring Hearts: Dilated Cardi …
Newark, New Castle, USA: The "Dilated Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Dilated Cardiomyopathy Market: https://www.growthplusreports.com/report/dilated-cardiomyopathy-market/7764 This latest report researches the industry structure, sales, revenue,
Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Hypertrophic Cardiomyopathy Therapeutics Market to Gain Significant Impetus from …
The global hypertrophic cardiomyopathy (HCM) therapeutics market is dominated by companies exhibiting high sales. However, generic manufacturers are making their presence felt in the market gradually. As per Transparency Market Research (TMR), the top three companies in the market, Sanofi S.A., Pfizer, Inc., and Merck & Co., accounted for a share of over 64.5%, which points toward a highly consolidated vendor landscape. Browse the Complete Details of this Report at: